Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix ZolgensmaⓇ grows +46% in 2021 to USD 1.4bn Due to geographic expansion as the foundational therapy for SMA Sales evolution USD m, % cc Ex-US US FY 920m FY 1.4bn +46% 375 342 319 315 291 254 249 205 224 200 169 209 170 148 44 100 126 122 105 106 119 126 106 118 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2020 2021 Q4 highlights CE zolgensma K &K L ■ Driven by expanding access ex-US, +58% sales ■ Over 1800 patients treated worldwide¹ Approval now in 42 countries; access pathways in 26 countries Newborn screening reached ~85% in US, 20% in EU Future outlook Continued growth ex-US ■ Newborn screening: Goal of 38% in EU by YE22 ■ US: Steady US sales driven by incident patients Advancing robust data in SMA with IT² ▪ STEER: Ph3 currently initiating treatment-naive Type 2 patients ■ STRENGTH: Start H2 2022 in patients who have discontinued treatment with nusinersen and/or risdiplam 1. Commercially, via managed access programs and in clinical trials 2. With investigational OAV101 intrathecal administration 28 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation